BioSpace News Archive

Susan G. Komen®, the world’s leading breast cancer organization, has launched the Stand for H.E.R. – A Health Equity Revolution Breast Cancer Impact Report.

Uvax Bio, LLC, (“Uvax” or “the Company”) today announced the first participant has been dosed in a Phase 1 clinical trial evaluating the Company’s HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, in healthy volunteers in Australia.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately.

NovaBay Pharmaceuticals, Inc. announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.

RION’s Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).

Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance for the Horizon 3.0 with StimGuide Pro.

Palisade Bio, Inc. announced an agreement between the Company and several accredited investors to exercise certain existing warrants to purchase up to an aggregate of 3,413,286 shares of common stock.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView

Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.

AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis, frontotemporal dementia, and other neurodegenerative diseases, announced that it has successfully raised nearly $7 million in grant funding for ALS / FTD research from the National Institutes of Health and the Department of Defense.